BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12728405)

  • 1. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
    Wahl RL
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):31-8. PubMed ID: 12728405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
    Hohenstein MA; Augustine SC; Rutar F; Vose JM
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):39-49. PubMed ID: 12728406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
    Zelenetz AD
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
    Vose JM
    Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
    Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
    Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
    Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure.
    Harwood SJ; Gibbons LK; Goldner PJ; Webster WB; Carroll RG
    Cancer; 2002 Feb; 94(4 Suppl):1358-62. PubMed ID: 11877766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
    Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
    Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
    Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
    Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
    J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.